Low-dose naltrexone (LDN) continues to attract interest as an off-label treatment for chronic neuropathic pain and inflammatory conditions. Patient experiences describe improvements in pain, sleep, and quality of life, although responses vary widely.
Current evidence suggests LDN may reduce neuroinflammation through glial cell modulation, but larger clinical trials are still needed. Treatment should always be supervised by a qualified healthcare professional, especially when other medications such as opioids are being used.
This content is for educational purposes only and does not replace professional medical advice.